|Bid||6,254.00 x 0|
|Ask||6,448.00 x 0|
|Day's range||6,226.00 - 6,312.00|
|52-week range||5,130.00 - 8,191.30|
|Beta (5Y monthly)||0.12|
|PE ratio (TTM)||N/A|
|Earnings date||24 Feb 2021|
|Forward dividend & yield||1.75 (2.79%)|
|Ex-dividend date||20 Aug 2020|
|1y target est||7,085.56|
Analysts at UBS say the outlook for UK equities has never been brighter.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
The company "Strongly believes that the claim is without merit and that it has strong grounds for defending against the claim should it be served," said Indivior, which was spun off from Reckitt in 2014. Indivior said that the claim has not been served yet. Last week, the British drugmaker disclosed that Reckitt had submitted a 1.07 billion pound claim earlier this month to the Commercial Court in London against Indivior relating to their demerger agreement.